News | Stents Drug Eluting | November 03, 2017

Biotronik Orsiro DES Shows Low Five-Year Event Rates

Vascular intervention/five-year results presented at TCT 2017 demonstrate high long-term safety and clinical performance of ultrathin drug-eluting stent

Biotronik Orsiro DES Shows Low Five-Year Event Rates

November 3, 2017 — Biotronik's Orsiro drug-eluting stent (DES) demonstrated high long-term safety and clinical performance according to 60-month follow-up data presented during the 2017 Transcatheter Cardiovascular Therapeutics Annual Conference (TCT 2017), Oct. 29-Nov. 2 in Denver.

Data from the BIOFLOW-II randomized controlled trial was presented in a poster session by Ton Slagboom, M.D., Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands, showing a target leisure failure (TLF) rate of 10.4 percent in the Orsiro group and 12.7 percent in the Xience study arm at 60 months (p=0.4728). No definite or probable stent thrombosis occurred during 60 months of follow-up in the Orsiro group (n=268). In the Xience group (n=132), one case of very late definite thrombosis was detected (0.7 percent) at five years.

In addition, data from BIOFLOW-III, a prospective, non-randomized, open-label, all-comers registry was presented in a poster session by Johannes Waltenberger, M.D., professor of cardiology and angiology at University Hospital Münster, Germany. Of an initially enrolled population of 1,356 patients, 898 patients consented for long-term follow-up. Among these patients, there was a follow-up compliance of 90 percent at 60 months. The TLF rate of the full cohort was 9.3 percent at 60 months and definite or probable stent thrombosis occurred in eight cases (0.7 percent, including two very late stent thromboses).

Long-term data for both trials demonstrate that the previously observed low TLF rates at 12 months persisted through the 60-month follow-up. Rates of definite and probable stent thrombosis remained low through 60 months, affirming the safety of the Orsiro stent system in the long term.

"In choosing a permanent implant, clinicians must always consider the long-term impact of their choices; with this data Orsiro joins the limited number of DES with proven favorable outcomes out to five years," commented Slagboom, an investigator in the BIOFLOW-II trial.

The new data presented at TCT 2017 supplements the existing body of evidence supporting the use of the Orsiro DES, with over 32,500 patients enrolled to date in the Orsiro clinical program. This includes the recently reported BIOFLOW-V study data, which showed significantly lower 12-month TLF rates compared to Xience.

For more information: www.biotronik.com

Related Content

Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Recent Acquisitions Eroding Prices in Billion Dollar European Interventional Cardiology cath lab Market.
Feature | Cath Lab | May 07, 2018 | Simon Trinh and Jeffrey Wong
The European interventional cardiology market is currently valued at nearly $1.4 billion.
Videos | Cath Lab | May 07, 2018
Imran Ahmad, M.D., medical director of interventional cardiology, explains some of the new technologies his labs have
360 Photos | Cath Lab | April 20, 2018
A 360 degree view of the newest cath lab at Northwestern Medicine Central DuPage Hospital in Winfield, Ill., located
SCAI Announces Global Lecture Series for 2018 Scientific Sessions
News | Cath Lab | April 18, 2018
Many of the world’s leading interventional cardiologists and cardiovascular professionals will convene in San Diego,...
Serial coronary angiograms of the representative case treated with shockwave intravascular lithotripsy.

Figure 1. Serial coronary angiograms of the representative case treated with shockwave intravascular lithotripsy.

Feature | Cath Lab | April 16, 2018 | Azeem Latib, M.D.
Over the last decade, there have been considerable developments in procedural techniques and technology facilitating
Overlay Init